Allarity Therapeutics, Inc. (ALLR) · Nov 19, 2026 · Other events
36 patent claims — Twice-daily stenoparib dosing protected into 2045
Allarity’s new patent protects stenoparib’s twice-daily dosing through 2045, strengthening its Phase 2 strategy without changing the clinical risk.
Allarity is a cash-constrained Phase 2 biotech advancing stenoparib through an expanded ovarian-cancer study and a separate small-cell-lung-cancer trial; it ended September with $24.1 million in cash and restricted cash. The filing adds a meaningful layer of commercial protection around the development plan. The 36 claims cover the twice-daily regimen Allarity says it intends to take toward pivotal trials, along with use in ovarian and other solid tumors. 〔0〕 Protection extending into 2045 also complements the company’s earlier stenoparib-specific companion-diagnostic patent. 〔1〕
The signal is positive, but it is infrastructure—not validation. This improves the asset’s potential partnering and exclusivity story, especially because the protected regimen is central to the current Phase 2 program. But the filing produces no new response, survival, safety, enrollment, regulatory, or financing milestone; patent value still depends on stenoparib generating convincing clinical data and the claims surviving any challenge. The company’s recent patent and DRP announcements make the broader IP strategy partly known, so the new information is mainly the specific dosing coverage and longer protection period.
Bottom line: This modestly strengthens Allarity’s stenoparib development and partnering setup, but it does not materially de-risk the drug itself. The core story remains a Phase 2 clinical gamble awaiting efficacy evidence.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!